Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Agenda
– Introduction
– Life Science in Ireland
– Our Journey
– How we work & why investors
choose Ireland
– What next ?
– Q&A
• A third of the worlds’ contact lenses are manufactured
in Ireland
A quarter of people with Diabetes, that is 30 million people
globally, rely on an injectable device manufactured by Becton
Dickinson, Nypro and West Pharma in Ireland
• 80% of the global supply of stents are manufactured in
Ireland by Medtronic, Boston Scientific, Abbot
Vascular and others
Half of all ventilators used in acute
hospitals around the world are made in
Ireland primarily by Medtronic in Galway.
• Breakthrough breast cancer drug Tykerb was
developed and is manufactured in Ireland by
GSK.
Ireland currently produces c.10% of the entire
global exports of infant milk formula.
Allergan’s global supply
of Botox is manufactured
in Westport
Ireland experts in manufacturing
Breakthrough drugs Enbrel and Remicadeused for treating rheumatoid arthritis are made by Pfizer in Dublin and Johnson &
Johnson and Merck in Cork.
Life Sciences in Ireland
4
Companies 10 of the top 10 Pharma co’s
13 of the top 15 Medtech co’s
Exports Exports €64bn
28% of total Irish exports
Manufacturing 90 plants, 40+ FDA approved, 22
Biotech sites
Employment 60,000
Education 50% are 3rd
level graduates
25% of all PhDs in Ireland are in
industry
Compliance Unrivalled record globally
Investment €10bn in biopharma in the last decade
Training National Institute for Bioprocessing,
Research & Training (NIBRT)
5
5 operations – 1,800
people. Bulk
chemicals, Global
Business Services,
Intraocular lenses and
global Chemical HQ
6 operations – 3,000
people. Bio, API,
Global Financial
Shared Services,
5 operations – 2,600
people.
Orthopaedics,
Contact lenses, Bio,
API, Global Supply
Chain
5 operations – 1,640
people. Bio, DP, Pharma
fill-finish, R&D, Tech Ops,
Financial Shared
Services, Supply Chain
5 operations – 1,600
people. API, OTC,
Oral Care, Consumer
Products and
Commercial Ops.
6 operations – 1,700
people. API, Biologics,
R&D, EMEA Shared
Services Centre
Value Chain – our sweet spot
6
So how do we do it ?
7
The Journey
8
2005 1967
Free Hi-School
education &
setting up
Institutes of
Technology
Ireland joins
the European
Economic
Community
19871973
Third Level
Education fees
abolished for
Undergraduates
199620162012
1992: “Culliton” - focus on areas of
productivity, reduced reliance on grants
and a bringing together of multiple
factors/institutions across the economy
1992
12.5% corporate
tax rate
2000
Enterprise Ireland spun off from IDA
to increase focus on indigenous
firms
1994
2003
Single European Act
to join the Single Market
Disruptive technologies
innovation fund
20181969
Tax
The Irish tax regime is open, transparent and complies fully with OECD guidelines and EU
competition law.
– Corporation Tax – 12.5%:
applies to all Irish corporate trading profits
it is not an incentive regime, rather it is Ireland’s standard tax rate applicable to active
business or ‘trading’ income.
– R&D Tax Credit - 25%:
Qualifying R&D expenditure generates a 25% tax credit for offset against corporation tax
Qualifying expenditure includes wages, related overheads, plant and machinery, etc
– Knowledge Development Box 6.25%:
First OECD-compliant Knowledge Development Box. A tax rate of 6.25% applied to
profits from intellectual property i.e. profits from research and development
undertaken in Ireland.
9
1
0
GOAL
▪ Attracting and embedding FDI
in the Republic of Ireland
▪ 2017 turnover of €200m,
▪ Of this, €90m was given to
firms in grant funding
▪ Government agency with
considerable autonomy
▪ 22 international offices situated
across 4 continents
▪ 10 offices across the Republic
▪ Promoting the indigenous
business sector, with a
particular focus on exporting
firms
▪ 2017 turnover of around
€370m, of which €250m was
spent on financial support to
industry
▪ € 490m under management in
the seed and venture
▪ capital schemes
▪ Government agency with
▪ 31 international offices in 28
countries, with support services
provided in another 35+
countries
▪ Attracting and supporting world
class scientific researchers in
the Republic of Ireland
▪ Awarded €175m in grants in
2017
▪ Public organisation responsible
for distributing research grants
to recruit and retain research
groups
STATUS FUNDING
SOURCE: Literature review; press search; expert interviews
Key Agencies
Irish RD&I Landscape
Department of Business, Enterprise & Innovation
Supporting Research and Innovation for the Future
Supporting Indigenous Irish Companies
In-house R&D and applied Research
for MNC’s
0. Idea
1. Basic research
2. Technology formulation
3. Applied research
9. Full commercial application
RDI Funding Spectrum
SFI
4. Small scale prototype
5. Large scale prototype
6. Prototype system
7. Demonstration system
8. First of a kind commercial system
EIIDA
Variety of Supports Across Agencies
12
Financial
Supports
Capital and
Employment
Grants
(IDA)
SFI Industry Access
Innovation
Partnership
(EI)
Training
(IDA)
RDI
Programme
(IDA)
Feasibility
Programme
(IDA)
Knowledge
Development Box
6.25%
25% R&D Tax
Credit
12.5% Corporate
Tax Rate
SFI Research Centres
13
ADAPT Centre for Global Digital Content and Engagement
AMBER Advanced Materials and BioEngineering Research Centre
APC APC Microbiome Institute
CONNECT Future Broadband, Cellular and Internet of Things Networks
CÚRAM Centre for Research in Medical Devices
iCRAG Irish Centre for Research in Applied Geosciences
INFANT Irish Centre for Fetal and Neonatal Translational Research
INSIGHT Centre for Data Analytics
IPIC Irish Photonic Integration Research Centre
LERO Irish Software Research Centre
MaREI Marine and Renewable Energy Ireland
SSPC Synthesis & Solid State Pharmaceutical Centre
CONFIRM Smart Manufacturing IT and industrial automation systems
FutureNeuro Diagnosis, monitoring and treatment of neurological diseases
I-Form Innovative techniques and processes in Additive Manufacturing
BEACON Bioeconomy – extracting new value from biological wastes and residues
About IDA
Established 1969
– Government Agency (Department of Business, Enterprise & Innovation)
– Independent Board & CEO
– Overseas & Irish Offices (350 staff)
Mission:
– Attract multinational companies to invest in Ireland
– To provide jobs for the economic and social benefit of Ireland
Key sectors:
– Technology
– Consumer and Business Services
– Bio Pharmaceuticals
– Medical Devices
– Financial Services
– Engineering
14
Austin
BeijingTarget a minimum increase in investment of 30% to 40% in each region outside Dublin ……Dublin to continue to achieve the same high level of investment
How we work with companies
Evaluation & Site
Selection
Decision &
Implementation
Continuous
“After-Care”
• Organise Site-Visits to Ireland
• Provide “Due Diligence” information
• Open doors to the business community in Ireland
• Grant Aid (Regional Employment, RD&I, Training)
• Assistance with Property & Office solutions
• Press & PR
• Introductions at Government level
• Employee Work Permit / Visa support
• Influencing Government on behalf of industry
Suite of Support Services provided by IDAPhases of
Development
Galway
Dundalk
Letterkenny
Sligo
Athlone
Carrigtwohill
Ballina Cavan
College Park
Killarney
Mullagharlin SS
Cruiserath/College Park/Grange Castle SS
Greystones SS
Belview SS
Ballyadam / Carrigtwohill East SS
Ringaskiddy SS
NTP SS
Oranmore SS
Athenry SS
Raheen SS
IDA property
16
IDA
founded
State
funded
advanced
factories
built
1970’s
Private sector
built factories
for IDA
State
guaranteed 35
year lease on
buildings and
sublet them to
companies
1980’s 1995
Regional
Agenda
Land
holdings
increased in
regions
2000’s
Business and
Technology
Parks model
developed
1969
Private Sector
funded the
buildings
35 Business Parks c.1,251.0 ha
12 Strategic Sites c.942.5 ha
Total c.2,193.5 ha t
1990’s
Strategic Sites
model
developed
– 4,000 people received training in NIBRT in 2017.
– 6500m2
GMP-like facility:
Pilot scale Training and Research Facility
Upstream and Downstream Bioprocessing (Stainless Steel and Single use)
Sterile Fill finish training
Bioanalytical research & training
– NIBRT is teaming up with Philadelphia’s Thomas
Jefferson University to set up the first education and
training centre for biologics manufacturing in North
America. The collaboration is valued at about $10
million.
– Single use collaboration with GE Healthcare
18
19
Trends in BioPharmaceuticals: What Tech is
Emerging?
Niche Busters/
Molecularly Targeted
Therapeutics
Next Gen
Therapeutic
Formats
ADC’s Bispecific Ab’s Cell/Gene Therapy
Next Gen
Manufacturing
Supporting Manufacturing Evolution
– Over the next decade Pharma Manufacturing will evolve
– Embracing disruptive technologies will be required to;
• Reduce manufacturing costs
• Improve quality control
• Eliminate shortages
• Enhance compliance
• Reduce Risks
Factories of the Future:
21
Manufacturing 4.0
Additive ManufacturingCollaborative Robotics
CyberSecurity Data Analytics
IIoT
Virtual Reality
Manufacturing Informatics
22
Ireland – robust ecosystem
Last word
– “It is not the strongest of the species that survives, nor the most
intelligent that survives. It is the one that is the most adaptable
to change.”
– In the long history of humankind (and animal kind, too) those
who learned to collaborate and improvise most effectively have
prevailed.
23
24
To learn more log on to idaireland.com
+353 1 603 4000
Shay Power,
IDA Ireland, Dublin
Mobile: 087 2472379
Email: [email protected]